Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Date:8/29/2007

dam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy to become a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Condensed interim financial statements 30 June 2007

The attached consolidated income statement, balance sheet and cash flow statement are derived from our condensed interim financial statements 30 June 2007 which can be found on our website http://www.amtpharma.com

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors,
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Detect Single Nucleotide Sequence Changes with Mx4000 Molecular Beacon Allelic Discrimination Kits
2. Genotyping Single Nucleotide Polymorphisms with Molecular Beacons
3. New Protocols for Isolating High- Molecular-Weight Genomic DNA
4. HSVision Molecular Beacon Detection Module Rapidly Detects Herpes Simplex Virus DNA
5. Molecular Biology:Easy Dephosphorylation and Rapid DNA Ligation
6. Isolation of Low Molecular Weight Digestion Products of the Human Platelet Thromboxane A2 Receptor, Rev A
7. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
8. Measurement of proteasome inhibition in live cells in Molecular Devices microplate fluorometers
9. Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36)
10. Kodak in vivo imaging system: precise coregistration of molecular imaging with anatomical X-ray imaging in animals
11. Near Infrared Technology and Optical Agents For Molecular Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... Oct. 27 /Xinhua-PRNewswire/ -- Recently, China Green,Material ... Intellectual,Property Office for two patents for Industrialized ... and Industrialized Production,Method of Fully Biodegradable Edible ... applications have both obtained acceptance numbers,200810064592 and ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) today ... study,demonstrating that repeat administration with TRU-015 continues ... rheumatoid arthritis,(RA) signs and symptoms based on ... announced positive results following preliminary,analyses from a ...
... Inc. ("Carna"),announced on October 27, 2008, the signing ... ("SUBC"). Under the terms of this,Agreement, SUBC will ... China., With China,s emergence as a strong ... companies have now established,research and production facilities in ...
Cached Biology Technology:Patent Technologies Keep CGMT in a Leading Position in the Industry 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company 2
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... Report Issued by Small Cap IR. In 2011, Nilson Report,s ... at merchants on the leading payment cards rose to $135.3 ... and prepaid cards reached 6.54 billion.  Eight million credit card ... in 2012, and credit and debit card fraud resulted in ...
(Date:1/22/2015)... 22, 2015   EyeLock, Inc. , a market leader of ... Steve Gerber to the new role of Senior Vice ... leading development of mobile platforms and wearable solutions for EyeLock,s ... innovation in the semiconductor industry to his role at EyeLock, ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... MD Researchers from The Johns Hopkins Medical Institutions ... immunohistochemistry to distinguish hydatidiform moles. The related report ... Analytic Validation of a Multiplex Short Tandem Repeat ... The Journal of Molecular Diagnostics . Molar ...
... of sediment cores indicates that biological and chemical changes occurring ... 200,000 years and likely are the result of human-caused climate ... of Colorado at Boulder. While environmental changes at ... be tightly linked with natural causes of climate change -- ...
... 20 Aware, Inc. (Nasdaq: AWRE ), a leading ... results for its third quarter ended September 30, 2009. ... Officer, said, "Earlier today, we announced an agreement to sell ... new fabless semiconductor company being spun out of Infineon. ...
Cached Biology News:Classifying molar pregnancy 2Arctic lake sediments show warming, unique ecological changes in recent decades 2Arctic lake sediments show warming, unique ecological changes in recent decades 3Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
Normal sheep serum collected from healthy normal sheep...
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Biology Products: